Inspire's Category I CPT code for Inspire V: what it signals for device reimbursement

What the company has said

Inspire Medical Systems, the US maker of a neurostimulation therapy for sleep apnea, published an investor presentation in November 2026. According to the filing summary, the deck flags a new Category I CPT code for Inspire V from 2028. It also covers final 2027 Medicare payments, a growth plan and the company's full-year 2026 outlook.

That is the full extent of what the records tell us. They do not give the code number, the payment levels, the procedures the code will describe, or the financial guidance. We do not yet know how the 2028 code relates to the coding used for the current system. This article therefore looks at what the announcement signals and what market access teams should check, rather than at numbers.

Why a Category I code matters

CPT codes are the procedure codes US payers use to identify and pay for medical services. Category I codes are the permanent set. Category III codes are temporary and track emerging technologies. A Category I code generally signals that a procedure is established enough for routine claims processing, and it gives payers a stable basis for coverage and payment policy.

For a device-led therapy, the code often matters as much as the clearance. A procedure's description, its place in the code set and the payment attached to it affect surgeon and facility economics, and therefore adoption. The deck's pairing of the code with final 2027 Medicare payments suggests the company sees coding and payment as linked parts of its growth case. That is an inference from the deck's structure, not a statement in the records.

The timing gap

The code is flagged for 2028, while the final Medicare payments in the deck are for 2027. That leaves a transition year in which payment rules and coding for the new generation of the system may not match. Medicare payment rates are set through annual rulemaking, usually for physicians and for hospital outpatient settings. Commercial payers often follow Medicare's coding and sometimes its rates, but they apply their own medical policies and prior-authorisation criteria.

Whether the 2028 code changes how Inspire V procedures are described, grouped or paid is not in the records. Those details will determine whether this is a clean coding step or a more complicated change for providers, billing departments and payers. Teams should wait for the code descriptors and the related payment rulemaking before modelling anything.

A European contrast: registries and managed entry

The US pathway turns on coding and payment. Several related records show how differently European access runs. On 31 October 2026, Italy's AIFA closed the Managed Entry Agreement procedures and the monitoring registry for HOLOCLAR in its registered indication. Patients first treated before the cut-off stay under existing arrangements. The same day, AIFA activated a web monitoring registry and published monitoring forms for Nucala (mepolizumab) in reimbursed uncontrolled eosinophilic COPD, following a determination announced in the Official Gazette.

In Italy, then, reimbursement for medicines is tied to registry-based monitoring that can be opened or closed by agency decision. In the US device context in the lead record, the main levers are a procedure code and an annual payment cycle. The comparison is illustrative only, since the records connect neither Inspire to AIFA nor devices to medicines. Multinational teams still need to track both kinds of mechanism.

Who is affected and what to watch

The most directly affected are US-focused market access, reimbursement and health economics teams at Inspire and at competing or adjacent neurostimulation and sleep apnea device companies. Providers, billing and coding staff and payers' medical policy teams are also affected. Other device makers can read the announcement as an example of coding strategy being presented to investors as a growth driver.

Several items are still open. The first is the code's descriptor and effective date in the official code set. The second is how the final 2027 Medicare payments apply to the procedures Inspire's therapy relies on. The third is how commercial payers update their policies for the new generation of the system. The records do not address any of these, and the company's full-year 2026 outlook is not quantified in them.